Related Experiment Video

Updated: May 12, 2026

Ex Vivo Culture of Circulating Tumor Cells in the Cerebral Spinal Fluid from Melanoma Patients to Study Melanoma-Associated Leptomeningeal Disease
06:25

Ex Vivo Culture of Circulating Tumor Cells in the Cerebral Spinal Fluid from Melanoma Patients to Study Melanoma-Associated Leptomeningeal Disease

Published on: March 29, 2024

IGF-1R as an anti-cancer target--trials and tribulations

Helen X Chen1, Elad Sharon

  • 1National Cancer Institute, Bethesda, MD 20892, USA. helen.chen@nih.gov

Chinese Journal of Cancer
|April 23, 2013
PubMed

Insights

Targeting the insulin-like growth factor 1 receptor (IGF-1R) shows promise in specific cancers like Ewing sarcoma. However, broad application in adult tumors requires identifying predictive markers and combination therapies for improved outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The Type I insulin-like growth factor receptor (IGF-1R) is implicated in cancer growth and development.
  • Targeting the IGF pathway has become feasible with recent advancements in therapeutic agents.

Purpose of the Study:

  • To review the different classes of IGF-1R inhibitors.
  • To evaluate the clinical activity and challenges of IGF-1R inhibitors in various cancers.
  • To discuss future directions for IGF-1R-targeted therapy.

Main Methods:

  • Review of clinical trials involving IGF-1R inhibitors.
  • Categorization of inhibitors into monoclonal antibodies (anti-IGF-1R, anti-ligands) and tyrosine kinase inhibitors.
  • Analysis of clinical outcomes in different tumor types.

Main Results:

  • Over 10 IGF-1R inhibitors have entered clinical trials, targeting IGF-1R or its ligands.
  • Clinical activity observed in select tumors like Ewing sarcoma and thymoma.
  • Limited success in large trials for adult tumors (e.g., lung, breast, pancreatic cancer) attributed to pathway complexity and lack of biomarkers.

Conclusions:

  • IGF-1R is a validated target for specific cancers.
  • Future success depends on identifying predictive biomarkers and rational combination strategies.
  • Further research is needed to overcome challenges in IGF-1R-targeted cancer therapy.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.